ABSTRACT Background: The recommendations in the 2013 American College of Cardiology/American Heart Association (ACC/AHA) blood cholesterol guidelines expanded the indications and level of intensity of statin therapy for the primary prevention of cardiovascular disease. We assessed the treatment and cost implications of these guidelines within a cohort of active duty service members. Methods: Using the military electronic medical record system, the Armed Forces Health Longitudinal Technology Application, we randomly selected 1,000 active duty persons aged 40 yr or older and reviewed their lipid profiles and medical records to identify risk factors for atherosclerotic cardiovascular disease. We compared the recommended cholesterol treatment under the new ACC/AHA guidelines versus the Third Adult Treatment Panel of the National Cholesterol Education Program. Findings: The mean age was 49 ± 7 yr, 36% were female, 22% were on baseline statin therapy (4% high intensity), and 13% were not at Third Adult Treatment Panel cholesterol goal. There was no difference in the proportion eligible for statin therapy between ACC/ AHA and Third Adult Treatment Panel guidelines. Statin treatment under the ACC/AHA guideline resulted in a mean statin dose increase from 25 ± 20 mg to 36 ± 25 mg (p < 0.001) with an increase in those eligible for high-intensity statin therapy, 6% to 11% (p < 0.001). These changes translated to higher estimated yearly statin acquisition costs, $40,197 versus $52,527 per 1,000 patient-years of treatment (p < 0.001). Discussion: Within a low-risk active duty population over 40 yr, application of the 2013 ACC/AHA cholesterol treatment guidelines may not significantly increase those eligible for statins, but may increase statin treatment intensity and costs.
INTRODUCTION
The 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol treatment guidelines expanded the indications and intensity of statin therapy for the prevention of cardiovascular disease. 1 Several new recommendations were made compared with the National Cholesterol Education Program Third Adult Treatment Panel (ATP III) guidelines published in 2001. 2 Statin therapy was recommended for all patients with clinical cardiovascular disease regardless of low-density lipoprotein (LDL) cholesterol level. 1 Second, stroke risk assessment was combined with coronary heart disease (CHD) risk assessment using the Pooled Cohort Equations. 1 Third, the threshold for statin therapy was lowered to asymptomatic patients with a 10-yr combined predicted atherosclerotic cardiovascular disease (ASCVD) risk of 7.5% or greater. 1 In contrast, the threshold for treatment of the same patient population using the ATP III guidelines was a predicted CHD risk greater than or equal to 10% or an LDL cholesterol level above 160 mg/dL. 2 Finally, the ACC/AHA guidelines shifted away from achieving a target LDL cholesterol level and toward achieving a percent reduction in LDL with clearly defined statin therapy intensities.
1 Table I outlines  the targeted groups in the 2013 ACC/AHA guidelines and  Table II outlines the LDL goals by risk category in the ATP III guidelines. Given these expanded recommendations for statin therapy, we sought to examine their impact on cholesterol treatment and the cost of implementing the new ACC/ AHA guidelines within a low-risk active duty military population in the USA.
METHODS
Using the Department of Defense Military Health System (MHS) electronic health record, we examined the medical records of 1,224 randomly selected active duty service members of age 40 yr or older. The oldest member enrolled was 71 yr old. At the time of enrollment, all participants were listed on active duty status and were living in the National Capital Area, defined as the District of Columbia, Virginia, and Maryland. We recorded risk factors, to include measured lipid and blood pressure values, and active cholesterol treatments within 5 yr before the on-line publication of the ACC/ AHA guidelines on November 12, 2013. Using a randomly generated computerized alphabetical list of active duty service members assigned to the National Capital Area, we enrolled participants until we reached a cohort of 1,000 participants with complete data. A total of 224 participants (22.3%) were excluded for missing information regarding race, blood pressure, or fasting cholesterol data within the past 5 yr. Participants already on cholesterol treatment were not excluded. The study was approved by the local Institutional Review Board and was conducted in accordance with institutional guidelines.
For each subject, we compared his or her actual cholesterol treatment, if any, at the time of enrollment on November 12, 2013 with the recommended cholesterol treatment under the 2013 ACC/AHA guidelines and the ATP III guidelines. Costs for each treatment strategy were calculated using Military Health System pharmacy prices for fiscal year 2013 (Table III) . Clinical risk factors were based on electronic health record review and International Classification of Diseases (ICD-9) coding.
When applying the new ACC/AHA guidelines, we calculated the 10-yr risk for ASCVD for each participant using the 2013 ACC/AHA Pooled Cohort Equations based on age, sex, race, systolic blood pressure, total cholesterol, high-density lipoprotein (HDL), treatment for high blood pressure, history of diabetes mellitus, or active smoking. Clinical ASCVD was determined if the participant had any prior ICD-9 codes for acute coronary syndromes, myocardial infarction, stable angina, coronary revascularization, stroke, transient ischemia attack, or peripheral arterial disease. The most recent fasting lipid data and an average of the last three systolic blood pressure measurements within 5 yr were used to calculate risk. If moderateintensity statin therapy was recommended, we used atorvastatin 20 mg daily with a cost of $0.50 per day for comparison. If high-intensity statin therapy was recommended, we used atorvastatin 80 mg daily with a cost of $0.49 per day, respectively. No change to cholesterol treatment was made for participants on an equivalent-intensity statin, regardless of whether or not in combination with another non-statin cholesterol drug. Figure 1 outlines the model used to apply the 2013 ACC/ AHA guidelines.
Similarly, when applying the old ATP III guidelines, ICD-9 coding was used to determine the presence of CHD, CHD risk equivalents, and major risk factors. Likewise, the most recent fasting lipid data and an average of the last three systolic blood pressure measurements were used to calculate risk. Using the ATP III Framingham risk tables, we calculated the 10-yr CHD risk for each participant, risk category for initiation of drug therapy, and LDL cholesterol goal. An LDL delta, defined as the percent difference between the participant's actual LDL level and the goal LDL level, was calculated for each participant. For participants with an LDL delta of less than 30%, we used simvastatin 10 mg daily with a cost of $0.04 per day. For participants with an LDL delta of 30% or greater, but less than 50%, we used atorvastatin 20 mg daily with a cost of $0.50 per day. For participants with an LDL delta of 50% or greater, we used atorvastatin 80 mg daily with a cost of $0.49 per day, respectively. For participants already on cholesterol treatment, but not at their calculated LDL cholesterol goal, we used the next higher dose of the same medication. If the participant was already on the maximum dose, we added extended release (ER) niacin (Niaspan) 500 mg daily with a cost of $0.51 per day. For participants already at LDL goal, their non-HDL cholesterol goal and corresponding non-HDL delta were calculated and managed in a similar manner as their LDL goal. Figure 2 outlines the model used to apply the ATP III guidelines. Continuous variables are expressed as mean ± 1 standard deviation (SD) and compared with the Student's t-test for independent groups. Categorical variables are expressed as frequencies (%) and compared by Pearson's Chi-square test. Statistical analysis was performed using Stata (Version 12.1; Statacorp, College Station, TX), and a two-tailed p-value < 0.05 was considered significant.
RESULTS
The final cohort included 1,000 patients (62% male) of mean age 49 ± 7 yr and 36% were female (Table IV) . Overall, patients were at low risk by 10-yr ATP III risk (mean = 3 ± 4%) and pooled cohort risk assessment (mean = 4 ± 4%). Approximately 22% of patients were on baseline statin therapy (4% high-intensity statin), 13% of patients were not at ATP III cholesterol goal, and 3% had a history of ASCVD.
There was no difference in the proportion eligible for statin therapy between ATP III and ACC/AHA guidelines (31% vs. 30%, respectively). Compared with ATP III, the recommended mean statin dose increased from 25 ± 20 mg to 36 ± 25 mg (p < 0.001) and the percentage of subjects eligible for high-intensity statin therapy increased from 6% to 11% (p < 0.001) according to the ACC/AHA guideline. As compared with ATP III, statin treatment under the ACC/ AHA guideline resulted in significantly higher estimated yearly statin acquisition costs, $40,197 versus $52,527 per 1,000 patient-years (p < 0.001). Table V Table VI .
DISCUSSION
Using a randomly generated cross-sectional cohort of active duty service members, we analyzed the cost impact of the 2013 ACC/AHA guidelines versus the 2001 ATP III guidelines and found a statistically significant increase in annual per-patient cost of $12.33 (p < 0.001). We used the cheapest high-intensity, moderate-intensity, low-intensity statins, and non-statin cholesterol agents available in the Military Health System in our application models for both guidelines to reduce our cost estimates.
In contrast to other recent studies comparing the 2013 ACC/AHA guidelines to the 2001 ATP III guidelines, 3, 4 we found that the recommendations for statin therapy did not significantly increase (6.5% vs. 7.8%), only the recommendation for a high-intensity statin increased (10.7% vs. 6.4%, p < 0.001). The most likely explanation for our findings was our low-risk military cohort of active duty service members with a mean age of 49 yr and with low rates of hypertension (25%), active smoking (3%), diabetes (4%), and clinical ASCVD (3%).
We recognize several limitations to our analysis. Whereas data were meticulously obtained from all available comprehensive military health care electronic health records, and patients with incomplete data were excluded, our analysis is retrospective and thus reliant on providers for accurate documentation of patient baseline characteristics. Although included patients were obtained at random from an expansive military health network, selection bias remains, given our population of predominantly male, Caucasian, and low-risk military personnel, and our results may not be generalizable to other populations or health networks. In the current era of cost containment, we made basic assumptions for our cost analysis that providers would choose the least expensive available formulary drugs (i.e., atorvastatin, simvastatin, and niacin) for cholesterol management. Nonetheless, providers might choose alternative medications due to underlying comorbidities (e.g., liver/kidney dysfunction), potential medication interactions, allergies, previous medication intolerance, and/or patient preferences. Finally, although patient risk and cost estimates represent the best available and current information, we recognize that cost estimates and patient risk factors are variable over time. Consequently, long-term accounting of patient risk, medication costs, prescription data, adverse effects from medication use, and adverse cardiovascular events may provide more informative cost-effectiveness data.
CONCLUSIONS
Within a low-risk active duty military population over 40 yr, application of the 2013 ACC/AHA cholesterol treatment guidelines may not significantly increase those eligible for statins, but may increase statin treatment intensity and costs.
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